STOCK TITAN
  1. Home
  2. News
  3. PEPG

PepGen Inc - PEPG STOCK NEWS

Welcome to our dedicated news page for PepGen (Ticker: PEPG), a resource for investors and traders seeking the latest updates and insights on PepGen.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect PepGen's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of PepGen's position in the market.

News
PepGen to Participate in Upcoming Investor Conferences
Rhea-AI Summary
PepGen Inc. (PEPG) to participate in investor conferences to discuss advancements in oligonucleotide therapies for neuromuscular and neurological diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.16%
Tags
conferences
-
News
PepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy
Rhea-AI Summary
PepGen Inc. receives FDA orphan drug and rare pediatric disease designations for PGN-EDO51, a therapy for Duchenne muscular dystrophy, highlighting the critical need for innovative treatments in severe neuromuscular diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.01%
Tags
none
-
News
PepGen Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments
Rhea-AI Summary
PepGen Inc. completes enrollment for PGN-EDO51 Phase 2 clinical trial cohorts, expects preliminary data by mid-2024. The company also initiates CONNECT2-EDO51 trial, anticipates accelerated approval. Financially, PepGen raises $80 million in a follow-on offering, extending cash runway to 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.98%
Tags
earnings
News
PepGen Announces Clearance of CTA by UK Medicines & Healthcare Products Regulatory Agency to Begin CONNECT2-EDO51, a Phase 2 Clinical Trial designed to support potential accelerated approval of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy
Rhea-AI Summary
PepGen Inc. (Nasdaq: PEPG) receives authorization from MHRA to initiate Phase 2 clinical trial for PGN-EDO51 in patients with Duchenne muscular dystrophy, aiming for accelerated approval.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.09%
Tags
clinical trial
-
News
PepGen Receives U.S. FDA Fast Track Designation for PGN-EDODM1 for the Treatment of Myotonic Dystrophy Type 1
Rhea-AI Summary
PepGen Inc. receives Fast Track designation from the FDA for PGN-EDODM1, a potential therapy for myotonic dystrophy type 1. The company aims to address the root cause of the disease and improve outcomes for patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.79%
Tags
clinical trial
-
News
PepGen Announces Pricing of $80.1 Million Underwritten Offering of Common Stock
Rhea-AI Summary
PepGen Inc. announced the pricing of an underwritten offering of 7,530,000 shares of its common stock at a price to the public of $10.635 per share, with expected gross proceeds of approximately $80.1 million. The offering aims to support the company's advancement of oligonucleotide therapies for severe neuromuscular and neurological diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.63%
Tags
offering
News
Mary Beth DeLena Joins PepGen as General Counsel and Secretary
Rhea-AI Summary
PepGen Inc. (Nasdaq: PEPG) has announced the appointment of Mary Beth DeLena as General Counsel and Secretary. DeLena brings over 20 years of experience advising global life science companies, with extensive expertise in business development, finance, securities, corporate governance, employment, and commercial law. Her previous roles at Alnylam Pharmaceuticals and Praecis Pharmaceuticals, as well as her legal career at Skadden, Arps, Slate, Meagher & Flom LLP, demonstrate her significant contributions to the growth and success of these companies. Mary Beth's appointment is expected to play a crucial role in advancing PepGen's goal of delivering next-generation oligonucleotide therapies for severe neuromuscular and neurological diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.17%
Tags
none
-
News
PepGen Announces First Patient Dosed in CONNECT1-EDO51 Phase 2 Clinical Trial of PGN-EDO51 for Duchenne Muscular Dystrophy Patients Amenable to Exon 51 Skipping
Rhea-AI Summary
PepGen Inc. (Nasdaq: PEPG) announced the dosing of the first patient in its CONNECT1-EDO51 Phase 2 trial, evaluating PGN-EDO51 for the treatment of Duchenne muscular dystrophy (DMD) patients. Preliminary data from the 5 mg/kg PGN-EDO51 dose level is expected mid-2024, with Phase 1 results showing peak exon 51 skipping of 3.8% and 100% of subjects demonstrating exon skipping. The company aims to develop therapies to improve the lives of people living with DMD.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.17%
Tags
clinical trial
-
News
PepGen Announces First Patient Dosed in Phase 1 FREEDOM-DM1 Clinical Trial of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)
Rhea-AI Summary
PepGen Inc. (Nasdaq: PEPG) announces dosing of the first patient in its Phase 1 clinical trial, FREEDOM-DM1, to evaluate PGN-EDODM1 for the treatment of DM1. The company anticipates proof-of-concept data in 2024, including safety, transcript splicing, and clinical outcome measures at the 5 mg/kg dose level. The trial is intended to enroll approximately 24 adult patients with DM1 to evaluate safety, tolerability, and clinical outcomes impacted in DM1.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.03%
Tags
clinical trial
News
PepGen Announces Appointment of Howard Mayer, M.D. to Board of Directors
Rhea-AI Summary
PepGen Inc. (Nasdaq: PEPG) appoints Howard Mayer, M.D. to its Board of Directors. Dr. Mayer brings extensive clinical development and regulatory experience to the company, enhancing its mission to revolutionize genetic therapies for severe neuromuscular and neurological diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.4%
Tags
management
Stock PEPG logo
PepGen Inc

Nasdaq:PEPG

PEPG Rankings

#3194 Ranked by Market Cap
#4809 Ranked by Stock Gains
N/A Ranked by Dividends

PEPG Stock Data

420.61M
16.89M
0.05%
76.67%
1.24%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Boston